LUPIN2,074.00

Lupin Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersSUNPHARMACIPLADRREDDYALKEMFORTISAUROPHARMALAURUSLABSMANKINDMcap ₹94,823 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations20,010.822,707.927,958.029,966.6
Other Income120.2195.8424.5475.7
Total Income20,131.022,903.728,382.530,442.3
Expenses
+ Cost of Materials Consumed4,142.24,457.44,621.94,806.9
+ Purchases of Stock-in-Trade2,958.72,642.62,867.02,995.3
+ Changes in Inventories-457.4-257.8-162.5-158.5
+ Employee Benefit Expense3,494.63,964.24,574.54,874.5
+ Finance Costs311.6294.9434.5452.4
+ Depreciation & Amortisation1,196.81,169.31,375.51,529.4
+ Other Expenses6,062.36,618.17,241.07,910.0
Total Expenses17,708.718,888.720,952.022,410.0
EBITDA3,810.55,283.38,816.09,538.3
EBIT2,613.74,114.17,440.58,008.9
Profit
PBT before Exceptional Items2,422.34,015.07,430.58,032.3
+ Exceptional Items0.00.0-557.9-557.9
Pretax Income2,422.34,015.06,872.67,474.4
+ Current Tax633.9990.71,527.42,020.9
+ Deferred Tax-147.2-282.0-10.3-97.5
Tax Expense486.7708.71,517.11,923.4
+ Share of Associates & JVs0.00.00.0-0.0
Net Income1,935.63,306.35,355.55,551.0
+ Net Income — Continuing Ops1,935.63,306.35,355.55,551.0
+ Other Comprehensive Income37.6-91.5440.4315.7
Total Comprehensive Income1,973.23,214.85,795.95,866.7
Net Income to Common1,914.53,281.65,332.85,528.8
Minority Interest21.124.622.622.2
Per Share
Basic EPS42.0571.95116.75121.01
Diluted EPS41.8771.69116.44120.73
Other Comprehensive Income — detail
+ Other Comprehensive Income-91.5440.4315.7
+ Items NOT to be Reclassified to P&L-13.7-23.4-6.43.9
+ Tax on Items NOT to be Reclassified-8.0-0.13.4
+ Tax on Items NOT to be Reclassified — alt tag-4.7
+ Items to be Reclassified to P&L50.6-76.1419.6302.2
+ Tax on Items to be Reclassified0.0-27.1-13.0
+ Tax on Items to be Reclassified — alt tag3.9
Comprehensive Income — Owners of Parent40.73,190.25,768.55,842.3
Comprehensive Income — Non-controlling Interests-3.124.627.424.4
Per Share — as-filed variants
Basic EPS — Continuing Operations42.0571.95116.75121.01
Diluted EPS — Continuing Operations41.8771.69116.44120.73
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit13,367.415,865.720,631.622,322.8
Gross Margin %66.8069.8773.7974.49
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)2,422.34,015.07,430.58,032.3
− Exceptional Items (reconciliation)0.00.0-557.9-557.9
Net Income Adj (tax-effected)1,935.63,306.35,790.25,965.3
EPS Adj42.0571.95126.23130.04
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value2.002.002.002.00
Paid Up Equity Capital91.191.391.491.5
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.